Allergan plc (AGN) formed double bottom with $165.12 target or 3.00% below today’s $170.23 share price. Allergan plc (AGN) has $57.72B valuation. The stock decreased 0.43% or $0.73 during the last trading session, reaching $170.23. About 3.09 million shares traded or 8.07% up from the average. Allergan plc (NYSE:AGN) has declined 31.36% since June 14, 2017 and is downtrending. It has underperformed by 43.93% the S&P500. Some Historical AGN News: ; 19/04/2018 – Greg Roumeliotis: And the mystery bidder competing against Takeda for Shire is…. Allergan, sources say. Story coming on; 27/04/2018 – blacq: Allergan moves in as Shire rebuffs $63 billion Takeda bid: sources NEW YORK/LONDON (Reuters) – Drugmaker Sh; 19/04/2018 – ALLERGAN PLC – COMPANY HAS HIRED MULTIPLE FINANCIAL ADVISORS TO ASSIST IN REVIEW OF THESE OPTIONS; 30/04/2018 – Fidelity Growth Discovery Adds Mylan, Exits Allergan; 19/03/2018 – Allergan at Investor Day Hosted By H.C. Wainwright Today; 19/04/2018 – ALLERGAN DOES NOT INTEND TO MAKE AN OFFER FOR SHIRE PLC; 16/05/2018 – FDA declines to approve Evolus Inc’s rival treatment to Botox; 29/05/2018 – ALLERGAN – AS A RESULT OF PACKAGING ERROR, ORAL CONTRACEPTIVE CAPSULES MAY PLACE USER AT RISK FOR CONTRACEPTIVE FAILURE AND UNINTENDED PREGNANCY; 30/04/2018 – ALLERGAN CEO SAYS SPLITTING COMPANY AMONG OPTIONS UNDER REVIEW; 14/03/2018 – Allergan Investor Day Scheduled By H.C. Wainwright for Mar. 19
Among 8 analysts covering Enbridge Income Fund (TSE:ENF), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Enbridge Income Fund had 26 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Scotia Capital given on Wednesday, April 19. Scotia Capital maintained it with “Outperform” rating and $37 target in Friday, November 4 report. As per Wednesday, April 19, the company rating was maintained by TD Securities. TD Securities maintained it with “Buy” rating and $37 target in Friday, November 4 report. The rating was upgraded by National Bank Canada to “Sector Perform” on Wednesday, January 25. The stock of Enbridge Income Fund Holdings Inc. (TSE:ENF) earned “Outperform” rating by National Bank Canada on Monday, November 9. The firm earned “Neutral” rating on Thursday, February 4 by Credit Suisse. BMO Capital Markets maintained the shares of ENF in report on Wednesday, April 19 with “Market Perform” rating. The stock of Enbridge Income Fund Holdings Inc. (TSE:ENF) earned “Market Perform” rating by BMO Capital Markets on Friday, December 8. JP Morgan initiated Enbridge Income Fund Holdings Inc. (TSE:ENF) on Tuesday, December 15 with “Neutral” rating. See Enbridge Income Fund Holdings Inc. (TSE:ENF) latest ratings:
The stock decreased 0.03% or $0.01 during the last trading session, reaching $29.48. About 480,500 shares traded. Enbridge Income Fund Holdings Inc. (TSE:ENF) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.
Enbridge Income Fund Holdings Inc., through its investment in Enbridge Income Fund, holds energy infrastructure assets in Canada. The company has market cap of $5.16 billion. It owns crude oil gathering pipelines and storage facilities in Alberta, Saskatchewan, Manitoba, Ontario, and Quebec; and crude oil storage terminals and caverns in Hardisty, Alberta. It has a 19.55 P/E ratio. The firm also holds a 50% interest in the 3,719-kilometre Alliance System, which transports natural gas from western Canada and the Bakken region to delivery points near Chicago, Illinois.
Among 29 analysts covering Allergan Inc. (NYSE:AGN), 20 have Buy rating, 0 Sell and 9 Hold. Therefore 69% are positive. Allergan Inc. has $400 highest and $15000 lowest target. $243.12’s average target is 42.82% above currents $170.23 stock price. Allergan Inc. had 125 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Thursday, October 19 by Mizuho. As per Wednesday, February 7, the company rating was maintained by Leerink Swann. The firm earned “Overweight” rating on Thursday, March 1 by Morgan Stanley. The rating was maintained by Mizuho on Thursday, November 17 with “Buy”. The firm has “Buy” rating by RBC Capital Markets given on Friday, July 14. The firm has “Outperform” rating by Leerink Swann given on Wednesday, October 28. The firm has “Buy” rating by Bank of America given on Wednesday, February 7. The stock of Allergan plc (NYSE:AGN) earned “Outperform” rating by Bernstein on Friday, May 26. The stock has “Hold” rating by Edward Jones on Wednesday, October 18. The stock has “Overweight” rating by Barclays Capital on Monday, January 29.
Analysts await Allergan plc (NYSE:AGN) to report earnings on August, 2. They expect $4.13 earnings per share, up 2.74% or $0.11 from last year’s $4.02 per share. AGN’s profit will be $1.40B for 10.30 P/E if the $4.13 EPS becomes a reality. After $3.74 actual earnings per share reported by Allergan plc for the previous quarter, Wall Street now forecasts 10.43% EPS growth.
Investors sentiment decreased to 0.5 in Q1 2018. Its down 0.75, from 1.25 in 2017Q4. It turned negative, as 1 investors sold Allergan plc shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 77,429 shares or 75.14% more from 44,210 shares in 2017Q4 were reported. Callahan invested in 15,273 shares or 0.53% of the stock. Frontier Invest Management Co has invested 0% of its portfolio in Allergan plc (NYSE:AGN). Grassi Inv Management, a California-based fund reported 42,335 shares. Mitchell Mcleod Pugh Williams invested 0.48% of its portfolio in Allergan plc (NYSE:AGN). Gemmer Asset Management Ltd Limited Liability Company invested 0.01% of its portfolio in Allergan plc (NYSE:AGN). Moreover, Cubic Asset Ltd Liability Corp has 0.1% invested in Allergan plc (NYSE:AGN) for 2,130 shares. & Management reported 0% of its portfolio in Allergan plc (NYSE:AGN).